ClinicalTrials.Veeva

Menu

BC179 Against Alcohol-Induced Damage

W

Wecare Probiotics

Status

Not yet enrolling

Conditions

Healthy

Treatments

Dietary Supplement: Placebo group
Dietary Supplement: Probiotic group

Study type

Interventional

Funder types

Industry

Identifiers

NCT06899620
WK20250323

Details and patient eligibility

About

To assess the effectiveness and safety of probiotic strain BC179 in reducing alcohol absorption in the gut, thereby lowering health risks, as measured by participants' hangover scores.

Enrollment

80 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

  • Inclusion Criteria:

    1. A history of long-term heavy alcohol consumption, equivalent to ethanol intake ≥40g/day for over 1 year. The conversion formula is: ethanol (g) = volume of ethanol-containing beverage (mL) × ethanol content (%) × 0.8 (specific gravity of ethanol);
    2. Body Mass Index (BMI) between 18kg/m² and 25kg/m²; Voluntarily signed a written informed consent form, agreeing to participate in this study;
    3. Agreed to comply with the study protocol and restrictions;
    4. Subjects (including male participants) have no plans for conception from 14 days prior to screening until 6 months after the end of the trial and voluntarily agree to use effective contraception.
  • Exclusion Criteria:

    1. Patients with various types of viral hepatitis, autoimmune liver disease, drug-induced liver damage, vascular liver disease, genetic metabolic liver disease, or primary liver cancer;
    2. Individuals who have recently consumed substances with similar functions to the tested product, potentially affecting the study results;
    3. Patients with severe allergies or immune deficiencies;
    4. Pregnant, breastfeeding, or women with plans for pregnancy;
    5. Individuals with severe diseases of vital organs such as cardiovascular, pulmonary, hepatic, renal conditions, or those with diabetes, severe thyroid disorders, metabolic diseases, malignant tumors, or severe immune system disorders;
    6. Individuals who have used antibiotics within the past two weeks;
    7. Participants who did not comply with the required consumption of the tested product or missed follow-ups, making it impossible to evaluate the effectiveness;
    8. Other participants deemed unsuitable by the researchers.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

80 participants in 2 patient groups, including a placebo group

Probiotic group
Experimental group
Description:
10B CFU/Sachet/Day BC179 before meals; Storage: Store in cool and dry place without sun exposure
Treatment:
Dietary Supplement: Probiotic group
Placebo group
Placebo Comparator group
Description:
Maltodextrin one Sachet/Day before meals; Storage: Store in cool and dry place without sun exposure.
Treatment:
Dietary Supplement: Placebo group

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems